Quest Diagnostics Incorporated P/E Ratio 2007–2025
Quest Diagnostics Incorporated reported 19.58 of price-to-earnings ratio for fiscal 2025. That was 3.0% higher than fiscal 2024. Compared with fiscal 2020, the change was +92.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 19.58 | +3.0% |
| FY 2024 | 19.01 | +8.9% |
| FY 2023 | 17.46 | -4.3% |
| FY 2022 | 18.24 | +79.9% |
| FY 2021 | 10.14 | -0.4% |
| FY 2020 | 10.18 | -31.6% |
| FY 2019 | 14.88 | +10.5% |
| FY 2018 | 13.47 | -10.4% |
| FY 2017 | 15.04 | -10.5% |
| FY 2016 | 16.80 | +42.4% |
| FY 2015 | 11.80 | -15.2% |
| FY 2014 | 13.91 | +86.2% |
| FY 2013 | 7.47 | -41.4% |
| FY 2012 | 12.76 | -14.3% |
| FY 2011 | 14.90 | +50.3% |
| FY 2010 | 9.91 | -14.0% |
| FY 2009 | 11.52 | -10.3% |
| FY 2008 | 12.84 | -41.8% |
| FY 2007 | 22.09 | — |
Source: Quest Diagnostics Incorporated SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open DGX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Quest Diagnostics Incorporated reported 19.58 of price-to-earnings ratio for fiscal 2025. That was 3.0% higher than fiscal 2024. Compared with fiscal 2020, the change was +92.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Quest Diagnostics Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeQuest Diagnostics Incorporated — frequently asked questions
What is Quest Diagnostics Incorporated's price-to-earnings ratio?
Quest Diagnostics Incorporated (DGX) reported price-to-earnings ratio of 19.58 for fiscal year 2025, per its SEC filings.
How has Quest Diagnostics Incorporated's price-to-earnings ratio changed over time?
Between fiscal 2007 and 2025, DGX's price-to-earnings ratio declined at roughly 0.7% per year (compound annual rate), from 22.09 to 19.58.
Where does this data come from?
Figures are computed from Quest Diagnostics Incorporated's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More DGX financial history
Full DGX fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →